Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas
Andrew Jallouk(Vanderbilt University Medical Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Amrita Chauhan(Unknown), Yazeed Sawalha(Cleveland Clinic), Alex F. Herrera(City of Hope), Steven M. Bair(University of Colorado Cancer Center), Shakthi Bhaskar(Vanderbilt University Medical Center), Allison M. Bock(Mayo Clinic), Amy Ayers(The University of Texas MD Anderson Cancer Center), Reid W. Merryman(Harvard University), Ajay Major(University of Colorado Cancer Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Narendranath Epperla(University of Utah), Gilles Salles(Memorial Sloan Kettering Cancer Center), Sonia Godbole(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Jennifer L. Crombie(Dana-Farber Cancer Institute), Lorenzo Falchi(Memorial Sloan Kettering Cancer Center), Swetha Kambhampati(City Of Hope National Medical Center), Omnia Farahat(The University of Texas MD Anderson Cancer Center), Geoffrey Shouse(City Of Hope National Medical Center)
Cited by 0
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
|Journal of Clinical Oncology|2018|574